The treatment of type 2 diabetes mellitus (T2DM) has undergone a radical change since the introduction of new-age antidiabetic drugs; the sodium-glucose co-transporter 2 (SGLT2) inhibitors and the dipeptidyl peptidase-4 (DPP-4) inhibitors. DPP4 inhibitors improve glycaemic control by reducing endogenous glucose production, and SGLT2 inhibitors reduce plasma glucose concentrations by inhibiting renal glucose reabsorption and promoting urinary glucose excretion. 1 Therefore, combining these mechanisms of action enhances their glucose-lowering effects and counteracts undesired effects on endogenous glucose production and glucagon secretion.
This combination therapy achieved better glycemic control and greater weight reduction without increasing the risk of hypoglycemia in patients with inadequately controlled T2DM. 1 In this regard, Boehringer Ingelheim India and Docplexus have organized a…